Laird Norton Wetherby Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,687	Closed	-$232K	–	953
2024 Q2	$232K	Sell	1,687 -98	-5%	-$13.4K	0.01%	793
2024 Q1	$246K	Buy	1,785 +24	+1%	+$3.28K	0.01%	806
2023 Q4	$232K	Sell	1,761 -112	-6%	-$12.9K	0.01%	810
2023 Q3	$211K	Buy	+1,873	New	+$197K	0.01%	805
2023 Q1	–	Sell	-1,841	Closed	-$220K	–	939
2022 Q4	$220K	Buy	+1,841	New	+$216K	0.01%	775
2021 Q4	–	Sell	-2,155	Closed	-$207K	–	950
2021 Q3	$207K	Sell	2,155 -123	-5%	-$11.6K	0.01%	850
2021 Q2	$222K	Sell	2,278 -20	-0.9%	-$1.92K	0.01%	831
2021 Q1	$224K	Buy	+2,298	New	+$241K	0.02%	708
2020 Q4	–	Sell	-2,199	Closed	-$211K	–	920
2020 Q3	$211K	Buy	2,199 +365	+20%	+$42.2K	0.02%	632
2020 Q2	$223K	Buy	+1,834	New	+$203K	0.02%	608

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's NBIX Position: Q3 2024 in Review

Laird Norton Wetherby Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 1,687 shares — an estimated $232K sold.

Laird Norton Wetherby Wealth Management first reported a position in NBIX in Q2 2020 and held it in 10 quarters. The position peaked at $246K in Q1 2024. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

Laird Norton Wetherby Wealth Management reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
Laird Norton Wetherby Wealth Management sold 1,687 Neurocrine Biosciences shares in Q3 2024, an estimated $232K.
Laird Norton Wetherby Wealth Management first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 10 quarters.
Laird Norton Wetherby Wealth Management's Neurocrine Biosciences position peaked at $246K in Q1 2024.
574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2024, filed 14 Nov 2024.